ARCA triammonium solution (100 mM)

ARCA (triammonium) solution (100 mM) (Anti-Reverse cap analog triammonium solution (100 mM); m 2 7,3'O Gppp triammonium solution (100 mM)) is a 5′-cap analog. ARCA (triammonium) solution (100 mM) carries a methyl group at the 3'-OH position of m7G, which ensures that the cap is ligated to the 5' end of mRNA in the correct orientation during in vitro transcription and prevents reverse ligation. ARCA (triammonium) solution (100 mM) enhances the translation efficiency and stability of mRNA. In human immature dendritic cells, both the translation efficiency and total protein expression of ARCA (triammonium) solution (100 mM)-capped mRNA are higher than those of conventional m7GpppG-capped mRNA. ARCA (triammonium) solution (100 mM) can be used in research related to cancer, infectious diseases and mRNA vaccines ^{[1] [2] [3]}.

In Vitro, ARCA (triammonium) solution (100 mM)-capped mRNA serves as the reference for translational efficiency and total protein expression in human immature dendritic cells, with a total protein expression of 1.00 and translational efficiency of 1.00^[1]. ARCA (triammonium) solution (100 mM) enables proper cotranscriptional capping of in vitro transcribed mRNA by preventing reverse cap orientation, thereby supporting mRNA translation efficiency and stability^[3].

References:
[1]. Kowalska J, et al. Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes. Nucleic acids research. 2014;42(16):10245-64.
[2]. Bednarczyk M, et al. Fluorescence-Based Activity Screening Assay Reveals Small Molecule Inhibitors of Vaccinia Virus mRNA Decapping Enzyme D9. ACS chemical biology. 2022 Jun 17;17(6):1460-1471.
[3]. Litvinova V R, et al. mRNA vaccine platform: mRNA production and delivery[J]. Russian Journal of Bioorganic Chemistry, 2023, 49(2): 220-235.